Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CST-103 + CST-107 pharmacodynamic crossover study in neurodegenerative disorders
2020-006067-28Phase 2Completed
- Sponsor
- CuraSen Therapeutics
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clenbuterol and nadolol in Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), Mild Cognitive Impairment (MCI) and 1 more (2 arms), sponsored by CuraSen Therapeutics. Primary endpoint: CNS pharmacodynamic signal. Started Nov 2021; status: completed.
02
Drugs
clenbuterolnadolol
03
Conditions
Parkinson's disease dementia (PDD)dementia with Lewy bodies (DLB)Mild Cognitive Impairment (MCI)Parkinson's disease (PD)
Beyond the preview
Go deeper on 2020-006067-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006067-28.